Cryoport, Inc. (CYRX)

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
BioLogistics Solutions Revenue	83.76M	78.14M	67.02M
BioStorage/BioServices Revenue	20.37M	18.36M	15.03M
Life Sciences Services Revenue	104.13M	96.50M	82.04M
Life Sciences Products Revenue	82.32M	79.68M	74.73M
Revenue (Other)	-104.13M	-96.50M	-82.04M
Revenue (Total)	186.45M	176.18M	156.77M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Americas Revenue	137.68M	131.26M	113.55M
Europe, the Middle East, and Africa (EMEA) Revenue	30.70M	25.13M	27.02M
Asia-Pacific (APAC) Revenue	18.07M	19.78M	16.20M
Revenue (Total)	186.45M	176.18M	156.77M

Adjusted EBITDA

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Life Sciences Services Adjusted EBITDA	2.87M	-1.22M	-12.48M
Life Sciences Products Adjusted EBITDA	14.75M	14.31M	12.69M
Operating Income (Total)	-39.62M	-36.81M	-121.67M

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Number of Supported Clinical Trials - Phase 1	316.00	313.00	299.00
Number of Supported Clinical Trials - Phase 2	369.00	361.00	321.00
Number of Supported Clinical Trials - Phase 3	94.00	86.00	81.00
Total Number of Supported Clinical Trials	779.00	760.00	701.00
Number of Commercial Cell and Gene Therapies (CGT) Supported	22.00	20.00	19.00

Data Source: Fiscal.ai Last updated: Aug 6, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 12, 2026

Data Sources Report a data error